PMID- 35343258
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20220401
IS  - 1526-2359 (Electronic)
IS  - 1073-2748 (Print)
IS  - 1073-2748 (Linking)
VI  - 29
DP  - 2022 Jan-Dec
TI  - Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients 
      With Metastatic Colorectal Cancer: A Phase II Trial.
PG  - 10732748221080332
LID - 10.1177/10732748221080332 [doi]
LID - 10732748221080332
AB  - OBJECTIVE: Irinotecan-based doublet chemotherapy strategy was standard 
      second-line backbone for patients with oxaliplatin-refractory metastatic 
      colorectal cancer. The aim of this study was to evaluate tolerability and 
      efficacy of raltitrexed combined with irinotecan biweekly administered as the 
      second-line therapy for mCRC patients. METHODS: The study was a prospective, 
      single-center, non-randomized, open-label phase II clinical trial. Patients with 
      mCRC after failure with oxaliplatin and fluoropyrimidine or its derivatives were 
      enrolled. Irinotecan (180 mg/m(2)) and raltitrexed (2.5 mg/m(2)) were given 
      intravenously on day 1. Cycles were repeated every 2 weeks. The primary endpoint 
      was progression-free survival (PFS), and the secondary endpoints included overall 
      response rate (ORR), disease control rate (DCR), overall survival (OS), and 
      adverse events (AEs). RESULTS: Between December 2012 and October 2016, 33 and 35 
      patients enrolled were assessed for response and safety, respectively. The ORR 
      was 8.6%, and the DCR was 71.4%. The median PFS was 4.5 months (95% CI 3.8-5.2). 
      The median OS was 12.0 months (95% CI 8.5-15.5). Four patients received 
      conversion therapy to no evidence of disease (NED), and 2 patients were still 
      alive with beyond 24 months survival. The most common grade 3/4 AEs were anorexia 
      (14.3%), vomiting (14.3%), nausea (11.4%), fatigue (8.6%), and leukopenia (8.6%). 
      No one died from treatment-related events. The incidence and severity of toxicity 
      were irrelevant to UGT1A1 status. CONCLUSIONS: The combination of irinotecan with 
      raltitrexed is an efficient, convenient, and acceptable toxic regimen for 
      second-line treatment for mCRC patients.
FAU - Cheng, Ke
AU  - Cheng K
AUID- ORCID: 0000-0002-6034-8872
AD  - Department of Abdominal Oncology, Cancer Center of West China Hospital, 
      34753Sichuan University, Chengdu, Sichuan, People's Republic of China.
FAU - Zhou, Yu-Wen
AU  - Zhou YW
AD  - Department of Biotherapy, Cancer Center of West China Hospital, 34753Sichuan 
      University, Chengdu, Sichuan, People's Republic of China.
FAU - Chen, Ye
AU  - Chen Y
AD  - Department of Abdominal Oncology, Cancer Center of West China Hospital, 
      34753Sichuan University, Chengdu, Sichuan, People's Republic of China.
FAU - Li, Zhi-Ping
AU  - Li ZP
AD  - Department of Abdominal Oncology, Cancer Center of West China Hospital, 
      34753Sichuan University, Chengdu, Sichuan, People's Republic of China.
FAU - Qiu, Meng
AU  - Qiu M
AD  - Department of Abdominal Oncology, Cancer Center of West China Hospital, 
      34753Sichuan University, Chengdu, Sichuan, People's Republic of China.
FAU - Liu, Ji-Yan
AU  - Liu JY
AD  - Department of Biotherapy, Cancer Center of West China Hospital, 34753Sichuan 
      University, Chengdu, Sichuan, People's Republic of China.
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - United States
TA  - Cancer Control
JT  - Cancer control : journal of the Moffitt Cancer Center
JID - 9438457
RN  - 0 (Quinazolines)
RN  - 0 (Thiophenes)
RN  - 7673326042 (Irinotecan)
RN  - FCB9EGG971 (raltitrexed)
SB  - IM
MH  - *Antineoplastic Combined Chemotherapy Protocols
MH  - *Colorectal Neoplasms/pathology
MH  - Humans
MH  - Irinotecan
MH  - Prospective Studies
MH  - Quinazolines
MH  - Thiophenes
PMC - PMC8961360
OTO - NOTNLM
OT  - chemotherapy
OT  - irinotecan
OT  - metastatic colorectal cancer
OT  - raltitrexed
OT  - second-line
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2022/03/29 06:00
MHDA- 2022/04/01 06:00
PMCR- 2022/03/26
CRDT- 2022/03/28 08:52
PHST- 2022/03/28 08:52 [entrez]
PHST- 2022/03/29 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
PHST- 2022/03/26 00:00 [pmc-release]
AID - 10.1177_10732748221080332 [pii]
AID - 10.1177/10732748221080332 [doi]
PST - ppublish
SO  - Cancer Control. 2022 Jan-Dec;29:10732748221080332. doi: 
      10.1177/10732748221080332.